Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Published: Nov 07, 2012
BETHLEHEM, Pa., Nov. 7, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has developed a novel ocular formulation for its client, Eyeon Therapeutics, Inc. The formulation, based on a polymer owned by Particle Sciences, provided superior clinical results in treating dry eye when compared to Systane®, the leading OTC dry eye product from Alcon. The results were published earlier this year in the Journal of Ocular Pharmacology and Therapeutics.
Mark Mitchnick, CEO of Particle Sciences notes that "Particle Sciences has seen an increase in the number of client's coming to us for ocular formulations. In this case, our staff came up with a new approach and worked with our client to take the idea from concept into clinical trials in a very short time."
Particle Sciences is an integrated provider of drug formulation and development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visitwww.particlesciences.com, email email@example.com or contact us at (610) 861- 4701 for information.
Contact: Maureen Mattera
SOURCE Particle Sciences